Eli Lilly and Company

Other

Alan David Palkowitz

Kenneth Jeff Thrasher

Kenneth Lee Hauser

Daniel Jon Sall

Kumiko Takeuchi

Gerald Floyd Smith

Ho-Shen Lin

Minsheng Zhang

Richard Waltz Harper

Jefferson Ray McCowan

Nickolay Y Chirgadze

Jon Kevin Reel

Winston S Marshall

Richard L Simon

Mitchell I Steinberg

Celia A Whitesitt

Sherryl L Lifer

William Pfeifer

K Jeff Thrasher

Donald B Boyd

Matthew Joseph Fisher

Charles David Jones

Henry U Bryant

Michael Enrico Richett

Robert J Foglesong

Michael Lyle Denney

Mary George Johnson

Michael P Lynch

Brian Stephen Muehl

Jolie Anne Bastian

Joseph A Jakubowski

Todd Jonathan Kohn

Venkatraghavan Vasudevan

Jeffrey A Dodge

Valentine Joseph Klimkowski

Timothy Alan Shepherd

Thomas Alan Crowell

Charles Willis Lugar, Iii

Jennifer Marie Tinsley

Roger L Robey

James Densmore Copp

Mark Louis Heiman

Charles A Alt

Andrew Michael Ratz

Sandra K Sigmund

Gary A Rhodes

William Harlan Gritton

William George Trankle

Scott Alan Jones

George J Cullinan

Michael Robert Wiley

Nicholas J Bach

Louis Nickolaus Jungheim

Kennan Joseph Fahey

Jeffrey Daniel Cohen

Shawn Christopher Miller

Raymond Francis Kauffman

David E Seyler

Venkatraghaven Vasudevan

Joseph Henry Kennedy

This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.

Growth hormone secretagogues

The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use.

Naphthyl compounds, intermediates, compositions, and methods of use

This invention is directed to a class of acrylic and propionic acid compounds and their use in the treatment of post-menopausal symptoms and restenosis. In other embodiments, the invention is directed to intermediates and to processes for the preparation of the acrylic and propionic acid compounds.

Acrylic and propionic acid compounds, intermediates, processes, compositions, and methods

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of defined compounds of formula I as thrombin inhibitors.

Thrombin inhibitors

Naphthyl compounds, intermediates, compositions, and methods

Acrylic and propionic acid compounds, intermediates, processes, compositions, and method

This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

Antithrombotic agents

The present invention is directed to methods for the modulation of cardiac function which comprise the administration of certain compounds, as defined herein, having growth hormone secretagogue activity.

Treatment of congestive heart failure with growth hormone secretagogues

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.

Antithrombotic Agents

The present invention is related to methods for treating pathological conditions resulting from an estrogen deficiency, such as cardiovascular disease and osteoporosis, and is further related to methods for treating estrogen-dependent cancer, such as breast and uterine cancer, employing compounds of formula I

This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.

Antithrombotic diamines

Growing community of inventors

Carmel, IN, United States of America

Alan David Palkowitz